- Home
- CEPV vs CMPX Comparison
CEPV vs CMPX Comparison
Compare CEPV & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPV | CMPX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.4M | 371.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CEPV | CMPX |
|---|---|---|
| Price | $10.35 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 72.1K | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.06 | $1.61 |
| 52 Week High | $10.36 | $6.88 |
Technical Indicators
Market Signals| Indicator | CEPV | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 49.46 |
| Support Level | $10.19 | $1.88 |
| Resistance Level | N/A | $2.47 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 87.50 | 70.73 |
Price Performance
Historical ComparisonAbout CEPV Cantor Equity Partners V Inc. Class A Ordinary Shares
Cantor Equity Partners V Inc is a blank check company.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.